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This is one of a series of BMJ summaries of new guidelines, which are
based on the best available evidence; they highlight important
recommendations for clinical practice, especially where uncertainty or
controversy exists.
Why read this summary?
Eachyear6%ofadultswillexperienceanepisodeofdepression,
and over the course of a person’s lifetime more than 15% of the
population will have an episode.
1-4 Depression (as defined by
the American Psychiatric Association
5) is the leading cause of
suicide and currently the fourth highest disease burden on
society in terms of its treatment costs, its effect on families and
carers, and its impact on productivity in the workplace.
Depressioncanbedisablinganddistressingandformanypeople
canbecomeachronicdisorder,especiallyifinadequatelytreated.
It is about two to three times more common in people with a
chronicphysicalhealthproblemthaninpeoplewhoareingood
physical health.
6 Chronic physical health problems can
precipitate and exacerbate depression, but depression can also
adversely affect outcomes of coexisting physical illnesses,
including increased mortality. Furthermore, depression can be
a risk factor for some physical illnesses, such as cardiovascular
disease.
7
This article summarises the most recent recommendations on
depression from the National Institute for Health and Clinical
Excellence (NICE): an updated guideline on the management
and treatment of depression in adults
8 and a new guideline on
depression focusing on adults with a chronic physical health
problem.
9Inbothguidelinesdiagnosiswasbasedonthecriteria
of the Diagnostic and statistical manual of mental disorders,
fourth edition (DSM-IV), which require the presence of at least
five symptoms and of impaired function persisting for at least
two weeks.
5
Recommendations
NICE recommendations are based on systematic reviews of the
best available evidence. When minimal evidence is available,
recommendations are based on the experience and opinion of
the Guideline Development Group (GDG) of what constitutes
good practice. Evidence levels for the recommendations are
given in italic in square brackets.
Identification and assessment
• Be alert to possible depression (particularly in people with
ahistoryofdepressionorachronicphysicalhealthproblem
withassociatedfunctionalimpairment)andconsiderasking
the following two questions:
- “During the last month, have you often been bothered by
‘feeling down,’ depressed, or hopeless?”
- “During the last month, have you often been bothered by
having little interest or pleasure in doing things?”
[Based on moderate quality validation studies]
• When assessing a person who may have depression,
conduct a comprehensive assessment that does not rely
simply on a symptom count. Take into account both the
degreeoffunctionalimpairmentand/ordisabilityassociated
with the possible depression to determine severity (as
defined in DSM-IV) and establish the duration of the
episode.[Basedonmoderatequalityobservationalstudies
and the experience and opinion of the GDG]
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Practice
PRACTICEPersistent subthreshold depressive
symptoms or mild to moderate depression
• For people with persistent “subthreshold symptoms of
depression”(symptomsthatarebelowtheDSM-IVcriteria
formajordepression)ormildtomoderatedepression(with
orwithoutachronicphysicalhealthproblem)andforthose
with subthreshold depressive symptoms that complicate
the care of the physical health problem, consider offering
one or more of the following low intensity psychosocial
interventions, guided by the person’s preference:
-Individual, guided self help based on principles of
cognitive behavioural therapy (CBT)
-Computerised cognitive behavioural therapy
-A structured, group based physical activity programme.
For people with a chronic physical health problem, also offer
group based peer support (self help) programmes.
[Alltheaboverecommendationsarebasedonmoderatequality
randomised controlled trials]
• Do not use antidepressants routinely to treat persistent
subthreshold depressive symptoms or mild depression in
people without a chronic physical health problem, but
consider antidepressants for those with:
-A history of moderate or severe depression, or
-Subthresholddepressivesymptomsthathavebeenpresent
for at least two years, or
-Subthreshold depressive symptoms or mild depression
persisting after other interventions
[Based on moderate quality randomised controlled trials and
the experience and opinion of the GDG]
• Do not use antidepressants routinely to treat subthreshold
depressive symptoms or mild depression in people with a
chronic physical health problem, but consider
antidepressants for those with:
-A history of moderate or severe depression, or
-Mild depression complicating the care of the physical
health problem, or
-Subthresholddepressivesymptomsthathavebeenpresent
for at least two years, or
-Subthreshold depressive symptoms or mild depression
persisting after other interventions.
[Based on moderate quality randomised controlled trials and
the experience and opinion of the GDG]
Starting antidepressants in people with
depression and chronic physical health
problem
• When prescribing an antidepressant, take into account:
-Any additional physical health disorders
-The side effects of antidepressants, which may affect the
underlying physical disease (in particular, selective
serotonin reuptake inhibitors may result in or exacerbate
hyponatraemia, especially in older people)
-The absence of evidence to support the use of specific
antidepressantsforpeoplewithparticularchronicphysical
health problems
-Interactions with other medications.
[Based on moderate quality randomised controlled trials and
observational studies]
• Prescribeaselectiveserotoninreuptakeinhibitoringeneric
form first, unless there are interactions with other drugs;
consider using citalopram or sertraline as they are less
likely to lead to interactions. [Based on moderate quality
randomised controlled trials and observational studies]
Moderate or severe depression
• For people with moderate or severe depression without a
chronic physical health problem, provide antidepressant
medication combined with high intensity psychological
treatment (CBT or interpersonal therapy). [Based on
moderate quality randomised controlled trials and health
economic modelling]
• Forpeoplewhofirstpresentwithmoderatedepressionand
a chronic physical health problem, offer group based CBT
(orindividualCBTforthosewhodeclinegroupbasedCBT
or for whom it is not appropriate, or where a group is not
available) or behavioural couples therapy. [Based on
moderate quality randomised controlled trials in people
withdepressionandchronicphysicalhealthproblemsand
on extrapolation from moderate quality randomised
controlled trials in people with depression]
• For people who first present with severe depression and a
chronic physical health problem, consider offering
individualCBTcombinedwithantidepressantmedication.
[Based on moderate quality randomised controlled trials
on people with depression and chronic physical health
problems]
Sequencing treatments after initial inadequate
response
• When reviewing drug treatment for a person with
depressionwhosesymptomshavenotadequatelyresponded
to initial pharmacological interventions:
-Checkadherenceto,andsideeffectsfrom,initialtreatment
-Increase the frequency of appointments, monitoring
outcomes with a validated outcome measure (such as the
hospitalanxietyanddepressionscale
10orthepatienthealth
questionnaire-9 (PHQ-9))
11
-Be aware that using a single antidepressant rather than
combinationmedication(twoantidepressantsusedtogether)
or augmentation (a non-antidepressant such as lithium or
an atypical antipsychotic used with an antidepressant) is
usually associated with fewer side effects
-Considerreintroducingprevioustreatmentsthathavebeen
inadequately delivered or adhered to, including increasing
the dose
-Consider switching to an alternative antidepressant.
[All the above recommendations are based on high quality
observational studies]
• When switching to another antidepressant, be aware that
the evidence for the relative advantage of switching either
within or between classes is weak. Consider switching to:
-First, a different selective serotonin reuptake inhibitor or
a better tolerated, newer generation antidepressant
-Subsequently, an antidepressant of a different
pharmacologicalclassthatmaybelesswelltolerated—for
example, venlafaxine, a tricyclic antidepressant, or a
monoamine oxidase inhibitor
-Inpeoplewithachronicphysicalhealthproblembeaware
of drug interactions.
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PRACTICE[Boththeaboverecommendationsarebasedonmoderatequality
non-randomised trials]
Continuation and relapse prevention
• Support and encourage people who have benefited from
takinganantidepressanttocontinuemedicationforatleast
six months after remission of an episode. [Based on
moderate quality randomised controlled trials]
• Offer people with depression (without a chronic physical
health problem) who are considered to be at substantial
risk of relapse or who have residual symptoms one of the
following psychological interventions:
-Individual CBT (for those who have relapsed despite
antidepressants or who have a history of depression and
residual symptoms despite treatment)
-Mindfulness based cognitive therapy (for those who are
currentlywellbuthaveexperiencedthreeormoreprevious
episodes of depression)
[Boththeaboverecommendationsarebasedonmoderatequality
randomised controlled trials]
People with chronic physical health problem
and moderate to severe depression not
responding to treatment
• Consider collaborative care for people with moderate to
severe depression and a chronic physical health problem
with associated functional impairment whose depression
has not responded to initial psychological interventions
(CBT or behavioural couples therapy), pharmacological
treatment, or a combination of both of these. [Based on
high quality randomised controlled trials]
• Such care should include case management supervised by
a senior mental health professional, close collaboration
between primary and secondary physical health services,
arangeofinterventionsconsistentwiththoserecommended
inthisguideline(includingpatienteducation,psychological
and pharmacological interventions, and medication
management), and long term coordination of care and
follow-up. [Based on high quality randomised controlled
trials]
Effective delivery of interventions for
depression
• All interventions for depression should be delivered by
competent practitioners.
• Base psychological and psychosocial interventions on the
relevant treatment manuals, which should guide the
structure and duration of the intervention.
• Practitionersshouldconsiderusingcompetenceframeworks
from the relevant treatment manuals, and for all
interventions they should:
-Receive regular, high quality supervision
-Use routine outcome measures and involve the person
with depression in reviewing treatment efficacy
-Monitor and evaluate adherence to treatment and
practitioner competence.
[Alltheaboverecommendationsarebasedonmoderatequality
randomised controlled trials, observational studies, and the
experience and opinion of the GDG]
Overcoming barriers
Under-recognition of depression remains a major problem, as
does the assessment of depression in the presence of chronic
physical health problems.
12 The new guidelines
8 9 offer specific
advice on how to overcome these problems, including
modification to assessment procedures in people with chronic
physicalhealthproblems.Evidencealsoexistsoflimiteduptake
of psychological interventions,
13 and this problem is addressed
by the recommendation of low intensity psychosocial
interventions for mild to moderate depression as part of a
stepped care framework. As evidence exists of considerable
variation in the competence of those providing psychological
interventions
14 both guidelines include a key recommendation
for effective delivery of interventions for depression.
Thenewguidelines
8 9alsoconfronttheconsiderablepessimism
that may exist about the effective treatment of depression, in
particular for those with a chronic physical health problem, by
identifying effective psychological and pharmacological
interventions.Uncertaintyaboutdruginteractions(inparticular
between the drugs used to treat depression and those used for
a physical health problem) may lead to inappropriate or
inadequateprescribingofantidepressants,thereforetheguideline
placesspecialemphasisonbeingawareofdruginteractionsand
offers advice about minimising risk. Prescribers who have
concerns are advised to consult the British National Formulary
(www.bnf.org) and the table of interactions in appendix 16 of
the full guideline
9 or to seek specialist advice or referral.
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PRACTICEAreas for future research and remaining uncertainties
• The most effective strategy for sequencing antidepressant treatment after inadequate initial response
• The efficacy of short term psychodynamic psychotherapy compared with cognitive behavioural therapy and antidepressants in treating
moderate to severe depression.
• The efficacy of CBT compared with antidepressants and placebo for persistent subthreshold depressive symptoms
• The efficacy of counselling compared with low intensity cognitive behavioural interventions and treatment as usual in treating persistent
subthreshold depressive symptoms and mild depression
• The efficacy of behavioural activation (an intervention that focuses on identifying effects of behaviours on current symptoms and seeks
to reduce the symptoms by using behavioural tasks such as reducing avoidance, scheduling activity, ensuring gradual exposure, and
initiating positively reinforced behaviours) compared with CBT and antidepressants in treating moderate to severe depression
• The efficacy and cost effectiveness of different systems for the organisation of care for people with depression
• The efficacy and cost effectiveness of cognitive behavioural therapy, interpersonal therapy, and antidepressants in preventing relapse
in moderate to severe recurrent depression
• The efficacy of peer support interventions compared with group based exercise and treatment as usual for patients with mild to
moderate depression and a chronic physical health problem
Further information on the guidance
A separate guideline for depression in people with a chronic physical health problem was developed because of the distinct needs of that population
(such as the challenges in identifying depression and engaging people in treatment, and some uncertainties surrounding the evidence base in this
population).
Despite the increased prevalence of depression in people with a chronic physical health problem, depression in this population is under-recognised.
1516
Therefore the guidelines recommend that clinicians be alert to depression in people with a chronic physical health problem. The diagnosis of depression
in DSM-IV includes cognitive, mood, and somatic symptoms (substantial weight change, sleep disturbance, fatigue or loss of energy, and psychomotor
retardation or agitation). However, somatic symptoms may arise not because of depression but because of the comorbid physical problem. Questions
focused specifically on non-somatic symptoms could improve detection of depression and reduce false positives in people with a chronic physical
health problem.
17 18
What’s new
The two new guidelines
8 9 act together as an update of an earlier guideline on depression.
19 The depression in adults guideline
9 also updates
recommendations for the treatment of depression included in a NICE technology appraisal of electroconvulsive therapy
20 and in a NICE review of
its earlier technology appraisal of computerised cognitive behavioural therapy for depression and anxiety.
21
The new guidelines adopt DSM-IV criteria
5 because nearly all of the evidence is based on studies in which depression is defined by these criteria.
The requirement for five symptoms—rather than four, as in ICD-10 (international classification of diseases, 10th revision)
22—to make the diagnosis
and emphasis on clinically important functional impairment may increase the threshold for more intensive interventions. The new guidelines cover
subthreshold depressive symptoms because these are recognised as potentially distressing and disabling if they are persistent and/or the treatment
of a chronic physical health problem is complicated by such symptoms.
The new guidelines together provide more extensive recommendations on low intensity psychological interventions and suggest the use of collaborative
care for people with persistent depression and chronic physical health problems. Recommendations on ensuring competence in all practitioners, in
particular psychological practitioners, are also included. New information on drug interactions relevant to the treatment of depression and chronic
physical health problems is also provided.
Brief methodology for these guidelines
The new guidelines were developed according to NICE guideline methodology (www.nice.org.uk/aboutnice/howwework/developingniceclinicalguidelines/
developing_nice_clinical_guidelines.jsp) by the National Collaborating Centre for Mental Health. Two groups of healthcare professionals and service
user and carer representatives were convened to oversee the work and develop the recommendations for both guidelines.
8 9 The groups conducted
extensive systematic reviews of the clinical and health economic literature.
Although the guidelines were developed by two distinct groups, both groups collaborated during the development process. Firstly, the literature
review and recommendations about case identification were the product of collaboration from both guideline development groups. Secondly, as
there was a substantially more limited evidence base for people with depression and chronic physical health problems, the guideline development
group considered the evidence from the depression in adults (update) group and extrapolated on the basis of this evidence when considered
appropriate. Extrapolation was based on several principles including (a) supplementing evidence for people with a chronic physical illness with that
from the general population where this was consistent in both populations, and (b) not extrapolating when evidence for people with chronic physical
illness and the general population was contradictory.
The guidelines went through an external consultation with stakeholders. The development groups assessed the comments, reanalysed the data
where necessary, and modified the guidelines. NICE has produced four different versions of each guideline: a full version; a quick reference guide
(which combines both guidelines); a version known as the “NICE guideline” that summarises the recommendations; and a version for service users
and the public (“Understanding NICE Guidance”). All these versions are available from the NICE website (www.nice.org.uk). Future updates of the
guidelines will be produced as part of the NICE guideline development programme.
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